Heni, M. et al. Elevated cholinesterase activity and the metabolic syndrome-dissecting fatty liver, insulin resistance and dysglycaemia. Liver Int. 45:e70046 (2025)
Heni, M.* ; Hummel, J.* ; Fritsche, A. & Peter, A. Response to Xu and Gao: Robustness of butyrylcholinesterase associations with liver fat and insulin sensitivity. Liver Int. 45:e70160 (2025)
Lynch, K.D.* et al. Navigating the hepatic immune landscape with fine needle aspiration of the liver-an emerging technique. Liver Int. 45:e70358 (2025)
Mantovani, A.* et al. Glucagon-like peptide-1 receptor agonists improve MASH and liver fibrosis: A meta-analysis of randomised controlled trials. Liver Int. 45:e70256 (2025)
Peters, B.* et al. Hepatic phenotype in NBAS-associated disease: Clinical course, prognostic factors and outcome in 230 patients. Liver Int. 45:e70146 (2025)
Schaefer, B.* et al. Penetrance, cancer incidence and survival in HFE haemochromatosis-A population-based cohort study. Liver Int. 44, 838-847 (2024)
Niedermayer, F. et al. Trajectories of glycaemic traits exhibit sex-specific associations with hepatic iron and fat content: Results from the KORA-MRI study. Liver Int. 43, 2153-2166 (2023)
Yaskolka Meir, A.* et al. Effects of lifestyle interventions on epigenetic signatures of liver fat: CENTRAL randomized controlled trial. Liver Int. 41, 2101-2111 (2021)
Xu, C.* et al. High-protein diet more effectively reduces hepatic fat than low-protein diet despite lower autophagy and FGF21 levels. Liver Int. 40, 2982-2997 (2020)
von Frowein, J.* et al. MiR-492 regulates metastatic properties of hepatoblastoma via CD44. Liver Int. 38, 1280-1291 (2018)